Health testing for men: Which lab updates and wearables actually matter?

The most useful men’s health monitoring combines a morning blood draw, done from 07:00 to 11:00, with a short list of high value metrics, especially total and free testosterone measured alongside LH and FSH when symptoms persist. Wearables can show daily changes in sleep, resting heart rate, and VO2 max, but lab updates reveal whether those trends reflect stress, poor recovery, metabolic trouble, or real hormone deficiency.

Key takeaways

• Many men now track health data through wearables, apps, and lab portals. The clinical value comes from a few reliable trends and targeted lab results, not from collecting every available metric.
• A 2020 systematic review found consumer wearables measured steps and heart rate accurately in laboratory settings, with accuracy varying by manufacturer and device, while no brand measured energy expenditure accurately.^[1] Calorie burn estimates are rough guides, not data to act on.
• Male hypogonadism is not diagnosed from one number alone. Persistent symptoms must match consistently low morning testosterone,^{[2] [3]} and LH plus FSH should be measured to find the cause.^{[2] [4]}
• In a small 2011 JAMA study of healthy young men, one week of sleeping 5 hours per night lowered daytime testosterone by 10 percent to 15 percent, one reason sleep tracking and lab updates often move together.^[5]
• In a 2009 JAMA meta analysis, each 1 MET increase in formally measured cardiorespiratory fitness was linked to 13 percent lower all cause mortality and 15 percent fewer cardiovascular events.^[6] Wearable VO2 max estimates are useful for personal trends but overestimate measured values, so they are not equivalent to exercise test results.^[7]

Why more men are tracking their numbers

Men’s health monitoring has shifted from a once a year physical to ongoing tracking of labs, fitness, sleep, recovery, and nutrition, because many midlife changes show up in data before they become obvious in daily life.

Body fat gain, rising insulin resistance, alcohol intake, medication effects, sleep debt, and lower activity can all push testosterone, blood pressure, and fitness in the wrong direction before a man is formally diagnosed with anything. The HPG axis, the hormone loop linking the hypothalamus, pituitary, and testes, is especially sensitive to these inputs. A 2010 New England Journal of Medicine analysis from the European Male Ageing Study defined late onset hypogonadism as at least three sexual symptoms together with total testosterone below 11 nmol/L (about 320 ng/dL) and free testosterone below 220 pmol/L (64 pg/mL), not a single borderline lab result.^[3] According to the 2018 Endocrine Society guideline, diagnosis requires symptoms and signs of testosterone deficiency plus consistently low testosterone on an accurate assay.^[2]

Wearables capture trends that reflect real physiology. A 2009 JAMA meta analysis found that each 1 MET increase in formally measured cardiorespiratory fitness was associated with a 13 percent lower risk of all cause mortality and a 15 percent lower risk of cardiovascular events.^[6] Watch estimates are a different measurement. A 2024 umbrella review in Sports Medicine found that wearables overestimated VO2 max by about 15 percent in resting tests and about 10 percent during exercise tests.^[7] A 2011 JAMA study found that restricting 10 healthy young men to 5 hours of sleep per night for 1 week reduced daytime testosterone by 10 percent to 15 percent.^[5] If VO2 max falls, resting heart rate rises, and morning erections disappear at the same time, that is a stronger signal than any single metric alone.

How health testing and biomarker tracking work together

Useful men’s health monitoring uses wearables for trends and lab testing for explanations.

Wearables are best for trends

According to a 2020 systematic review in JMIR mHealth and uHealth, commercially available wearables measured steps and heart rate accurately in laboratory settings, although accuracy varied by manufacturer and device type, and no brand measured energy expenditure accurately.^[1] The 2024 umbrella review in Sports Medicine added that wearables tended to overestimate total sleep time, typically with errors above 10 percent, and that only about 11 percent of commercially released devices had been validated for even one outcome.^[7] That makes wearables useful for watching trends in resting heart rate, training load, sleep duration, and estimated VO2 max, but weak as standalone diagnostic tools.

Lab testing finds what a smartwatch cannot

A biomarker is a measurable signal in blood that reflects a body process. For men with fatigue, libido changes, erection problems, fertility concerns, or unexplained recovery issues, a focused lab panel is usually more actionable than a large screening panel. A focused panel typically includes total testosterone, free testosterone, LH, FSH, estradiol, a complete blood count (CBC), a Comprehensive Metabolic Panel, vitamin D, PSA in men age 40 and older, and insulin when BMI is above 25.

A 2007 Endocrine Society position statement on testosterone measurement reviewed the limitations of clinical testosterone assays and called for laboratories to be judged on how accurately they measure samples of known testosterone concentration, not only on agreement with labs using the same method.^[8] The 2018 Endocrine Society guideline recommends a fasting morning total testosterone measurement with an accurate and reliable assay, repeated to confirm a low result.^[2]

Testosterone only makes sense in context

Total testosterone is the full amount circulating in blood. Free testosterone is the fraction not tightly bound to proteins and therefore available to tissues. Because protein binding can make total testosterone look acceptable when symptoms are real, the 2018 Endocrine Society guideline recommends measuring free testosterone by equilibrium dialysis, or estimating it with an accurate formula, when total testosterone is near the lower limit of normal or when a condition alters sex hormone binding globulin.^[2]

LH and FSH belong in the workup because they show where the problem sits.^{[2] [4]} High LH with low testosterone points to primary hypogonadism, meaning the testes are not responding. Low or normal LH with low testosterone points to secondary or functional hypogonadism, meaning the signaling pathway is underactive but may be reversible.

Lab updates should follow physiology

Daily wearable checks make sense because sleep, heart rate, and training stress change quickly. Hormone and safety labs do not need that frequency. For men on testosterone therapy, the 2018 Endocrine Society guideline recommends a standardized monitoring plan during the first year that covers symptoms, adverse effects, serum testosterone, hematocrit, and prostate cancer risk, since elevated hematocrit is a recognized adverse effect of treatment.^[2] The TRAVERSE trial, published in the New England Journal of Medicine in 2023, followed 5,246 men aged 45 to 80 with existing or high risk of cardiovascular disease for a mean of 33 months and found testosterone gel noninferior to placebo for major adverse cardiac events.^[9] The testosterone group had a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism.^[9]

Health problems this monitoring can flag

Biomarker tracking is most useful when it helps uncover specific, common problems, especially obesity related functional hypogonadism, sleep loss, cardiometabolic risk, and vascular causes of sexual symptoms.

Functional hypogonadism and metabolic syndrome. This is the most common real world pattern in midlife men. There is no structural damage to the HPG axis. Instead, obesity, insulin resistance, type 2 diabetes, and some medications suppress signaling to the testes. A 2011 meta analysis in The Journal of Sexual Medicine found that men with metabolic syndrome had significantly lower testosterone than healthy men, that type 2 diabetes deepened the drop, and that in longitudinal studies men who developed metabolic syndrome had started with testosterone about 2.2 nmol/L lower.^[10] Lifestyle changes can improve testosterone, but the rise is often modest, around 1 to 2 nmol/L, which is why men with persistent symptoms still need proper testing and treatment matched to the cause.

Sleep loss and possible sleep apnea. If a man’s wearable shows short sleep, fragmentation, or rising resting heart rate, and he also reports loud snoring, daytime sleepiness, and lower libido, the problem may be sleep disruption rather than a primary hormone disorder. Short sleep by itself lowered daytime testosterone in the 2011 JAMA sleep restriction study.^[5]

Low fitness and rising cardiovascular risk. Cardiorespiratory fitness predicts both mortality and cardiovascular events.^[6] When wearable VO2 max estimates trend down at the same time waist size, blood pressure, and glucose related labs worsen, the pattern points to cardiometabolic decline, not just a bad training block.

Erectile dysfunction and fertility clues. Erectile dysfunction often has a vascular cause rather than a hormonal one. A 2016 review in Nature Reviews Disease Primers described erectile dysfunction as a multidimensional disorder with organic, relational, and psychological components, strongly associated with metabolic syndrome and cardiovascular disease, and noted that cardiac assessment may be warranted in men with symptoms.^[11] Fertility concerns also require more than a testosterone number. LH and FSH help show whether the testes are being properly signaled, which directly affects treatment choice.

Signs you need a lab update, not just more app data

A lab update makes sense when symptoms last for weeks, repeat at the same time of day, or line up with falling performance and sleep quality.

• Your morning erections have become infrequent for a month or longer, and libido is down at the same time.
• You are sleeping 7 to 8 hours by the clock, but the wearable keeps showing repeated awakenings, and you are fighting daytime sleepiness or loud snoring.
• Your resting heart rate is running 5 to 10 beats per minute above your normal baseline for a week without a clear infection or travel disruption.
• Your watch estimated VO2 max is drifting down, and workouts that used to feel moderate now feel hard at the same pace, distance, or power output.
• Your waistline has grown by about 2 inches, or you are adding belly fat while strength, recovery, or libido are slipping.
• You are tracking calories and protein carefully, yet body composition keeps moving in the wrong direction and recent glucose or insulin testing is missing.
• You have erection problems, reduced orgasm quality, or lower ejaculate volume, especially if blood pressure, cholesterol, and hormone labs have not been reviewed recently.
• You have an outside testosterone result that looks acceptable on paper, but it was not a morning draw, did not include free testosterone, or left out LH and FSH.
• You started a treatment or major lifestyle change and have no plan for follow up labs.

Myth vs fact

Myth: More biomarkers always mean better health testing

Fact: A focused panel usually beats a bloated one. For men with symptoms, morning total testosterone, free testosterone, LH, FSH, estradiol, CBC, Comprehensive Metabolic Panel, vitamin D, PSA at age 40 and older, and insulin when BMI is above 25 are often more clinically useful than dozens of poorly actionable markers. Endocrine Society guidance centers on measuring testosterone accurately and confirming a low result, not on the number of markers tested.^{[2] [8]}

Myth: A normal total testosterone result rules out testosterone deficiency

Fact: Not always. Free testosterone can be more informative when protein binding distorts the picture, and diagnosis still requires persistent symptoms plus biochemical evidence on proper testing. The European Male Ageing Study and the Endocrine Society guideline both tie diagnosis to symptoms plus low testosterone, and the guideline asks for a repeat morning measurement rather than one random draw.^{[2] [3]}

Myth: Wearables can replace lab updates and medical evaluation

Fact: Wearables are useful for daily trends and habit feedback, but a systematic review found their accuracy is uneven across outcomes, especially energy expenditure.^[1] They can suggest that recovery, sleep, or fitness is worsening. They cannot tell you whether the cause is anemia, low testosterone, insulin resistance, thyroid dysfunction, medication effect, or something else.

Myth: TRT is the default answer whenever testosterone is low

Fact: Treatment should follow the cause. High LH with low testosterone suggests primary hypogonadism, where the testes are not responding. Low or normal LH with low testosterone suggests secondary or functional hypogonadism, where the hypothalamus and pituitary are under signaling and reversible causes deserve attention first. The 2018 Endocrine Society guideline recommends against starting testosterone therapy in men planning fertility in the near term.^[2] In a 2014 randomized phase II trial in Fertility and Sterility, men with secondary hypogonadism who took enclomiphene citrate raised morning testosterone to levels similar to those on topical testosterone gel, with increases in LH and FSH and conserved sperm counts.^[12]

What to do with your numbers

1. Step 1: Clean up the data for 2 to 4 weeks. Track sleep hours, alcohol, illness, training load, body weight, waist size, morning erections, and major symptoms. Save wearable trends, especially resting heart rate, sleep duration, and estimated VO2 max, but do not overreact to one bad night or one hard workout.
2. Step 2: Get a targeted morning lab panel. Draw blood from 07:00 to 11:00 and include total testosterone measured with an accurate assay such as LC-MS/MS, free testosterone, LH, FSH, estradiol, CBC, Comprehensive Metabolic Panel, vitamin D, PSA if you are age 40 or older, and insulin if BMI is above 25. Prolactin and thyroid testing are added when clinically indicated, especially in men with low or normal LH, pituitary red flags, or symptoms suggesting another endocrine cause.
3. Step 3: Confirm low or borderline testosterone on a repeat morning draw before final diagnosis and treatment decisions,^{[2] [4]} then choose treatment based on the pattern, not the trend line alone. If low testosterone with symptoms comes with high LH, the problem is primary, and testosterone therapy is the usual treatment. If low testosterone comes with low or normal LH, the pattern fits secondary or functional hypogonadism, and treatments that restart the body’s own signaling, such as enclomiphene, may fit, particularly when fertility matters. If erection problems are also present, they need their own evaluation and treatment.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have, with results interpreted by licensed providers across the U.S. When appropriate, those providers prescribe enclomiphene or a tablet combining enclomiphene with tadalafil. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

Bottom line

The lab updates and wearable metrics that matter are the ones that change decisions. For most men, that means pairing wearable trends in sleep, resting heart rate, and estimated VO2 max with a morning hormone and safety panel. That panel includes total and free testosterone, LH, FSH, CBC, Comprehensive Metabolic Panel, vitamin D, PSA at age 40 and older, and insulin when BMI is above 25. Any low testosterone result should be confirmed before treatment.

References

1. Fuller D, Colwell E, Low J, et al. Reliability and Validity of Commercially Available Wearable Devices for Measuring Steps, Energy Expenditure, and Heart Rate: Systematic Review. JMIR Mhealth Uhealth. 2020;8:e18694. PMID: 32897239
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
3. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-35. PMID: 20554979
4. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
5. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305:2173-4. PMID: 21632481
6. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009;301:2024-35. PMID: 19454641
7. Doherty C, Baldwin M, Keogh A, et al. Keeping Pace with Wearables: A Living Umbrella Review of Systematic Reviews Evaluating the Accuracy of Consumer Wearable Technologies in Health Measurement. Sports Med. 2024;54:2907-2926. PMID: 39080098
8. Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405-13. PMID: 17090633
9. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
10. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8:272-83. PMID: 20807333
11. Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003. PMID: 27188339
12. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102:720-7. PMID: 25044085